Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Sagimet Biosciences Inc. (NASDAQ : SGMT) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Quote
| Last: | $9.57 |
|---|---|
| Change Percent: | 1.27% |
| Open: | $9.57 |
| Close: | $9.57 |
| High: | $10.01 |
| Low: | $9.2801 |
| Volume: | 1,315,981 |
| Last Trade Date Time: | 08/11/2026 03:45:57 pm |
Stock Data
| Market Cap: | $183,421,818 |
|---|---|
| Float: | 25,724,585 |
| Insiders Ownership: | 0.29% |
| Institutions: | 25 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.sagimet.com |
| Country: | US |
| City: | San Mateo |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about Sagimet Biosciences Inc. (NASDAQ: SGMT).
